Celltrion Reports Preliminary Q2 2026 Consolidated Revenue of KRW 1.3 Trillion and Operating Profit of KRW 430 Billion, Up 35% and 77% YoY Respectively
Celltrion announced preliminary consolidated Q2 2026 revenue of KRW 1.3 trillion and operating profit of KRW 430 billion on July 3. This represents a 35.21% and 77.32% increase year-on-year, respectively. On a half-year cumulative basis, revenue reached KRW 2.445 trillion and operating profit KRW 751.9 billion, demonstrating strong growth.
The robust performance is attributed to expanded biopharmaceutical sales and new product launches. The operating margin improved significantly to 33%, which is a positive signal for shareholder value enhancement.
[AI Summary]Celltrion delivered strong operational results with high revenue and profit growth, but this is a preliminary release subject to audit adjustment. No capital changes or dividend announcements were made, limiting immediate shareholder return expectations.